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Cancer cachexia is characterized by a significant reduction in body weight resulting predominantly from loss
of adipose tissue and skeletal muscle. Cachexia causes reduced cancer treatment tolerance and reduced
quality and length of life, and remains an unmet medical need. Therapeutic progress has been impeded, in
part, by the marked heterogeneity of mediators, signaling, and metabolic pathways both within and between
model systems and the clinical syndrome. Recent progress in understanding conserved, molecular mecha-
nisms of skeletal muscle atrophy/hypertrophy has provided a downstream platform for circumventing the
variations and redundancy in upstream mediators and may ultimately translate into new targeted therapies.Introduction
One in four of the general population will die from cancer, and
cachexia affects the majority with advanced disease. The
syndrome of cancer cachexia is multifactorial and cannot be fully
reversed by nutritional support. It is caused by a combination of
reduced food intake and abnormal metabolism, seemingly
induced by tumor- and host-derived factors. It is not known
precisely how or why cancer so frequently develops in such
a way as to induce cachexia. Cachexia has commonly been
considered a paraneoplastic syndrome in which tumor-derived
factors induce widespread alterations in gene expression or
metabolic flux that may function to release intermediate metab-
olites, which can then be used by the tumor for growth and
expansion (Theologides, 1979). In this model, cachexia can be
considered a state of ‘‘autocannibalism’’ in which the tumor
survives at the expense of the host. In contrast, many of the
metabolic changes in cachexia are the result of activated
immune and neuroendocrine responses that are common to
trauma or sepsis and are thus more likely related to a generic
response to injury. In this model, cachexia may be regarded as
the downside of a double-edged sword designed to respond
to tumor-related noxious stimuli such as pain or tissue necrosis.
However, the existence of tumors with similar growth patterns
and identical origins, one of which induces cachexia while the
other does not (Monitto et al., 2001), implies that differences in
a limited number of genetic events or gene expression may
underlie the tumor phenotype associated with cachexia. For
example, patients with certain hematological malignancies or
Castleman’s disease classically exhibit ‘‘B symptoms’’ that
strongly parallel those of cachexia (fever, anemia, anorexia,
and weight loss). In Castleman’s disease, these symptoms are
ascribed either to the secretion of Kaposi’s Sarcoma associated
herpes virus-encoded interleukin-6 (IL-6) (Aoki et al., 2001) or
over secretion of human IL-6 (Ahmed et al., 2007). In such
circumstances the relative importance between IL-6 either
acting as an autocrine growth factor or promoting cellular growth
via substratemobilization, or functioning as part of a generic host
response, is as yet unresolved.Heterogeneity in the Clinical Presentation of Cachexia
It is only very recently that there has been progress in the devel-
opment of a framework for the definition and classification of
cancer cachexia (Fearon et al., 2011). Progress has been slow,
in part due to the heterogeneity in presentation of cachexia.
Cancer cachexia can vary according to tumor type, site, and
mass (Dewys et al., 1980). The anatomical position of a tumor
in the upper gastrointestinal tract may lead to obstruction and
reduce food intake directly. The relationship between cachexia
and tumor mass is complex. In many animal models the tumor
grows quickly and reaches >10% of body mass acting as
a ‘‘nitrogen trap’’ (Carrascosa et al., 1984). In humans, however,
tumor burden is often <1% when there is profound cachexia,
suggesting that the metabolic demands of the tumor are less
important than distant metabolic effects induced by the tumor
upon the host. For example, in pancreatic cancer, high tumor
IL-6 production has been associated with cachexia (Martignoni
et al., 2005), and increased levels of tumor-derived, or tumor-
induced but host-derived, proinflammatory cytokines is perhaps
the most common correlation between cancer and the preva-
lence of cachexia.
Evenwith the same tumor type and burden, one individual may
become cachectic whereas another will not. Such variation may
relate to host genotype. Genetic variation in immunity and asso-
ciated signaling pathways is known to relate to outcomes in
major sepsis (Thair et al., 2011), and recent findings suggest
a similar pattern in cancer cachexia. Single-nucleotide polymor-
phisms in the IL-1, IL-6, and IL-10 genes that are linked to
production rates of these cytokines have been associated with
the prevalence of cachexia in gastric or pancreatic cancer (Tan
and Fearon, 2010). For example, the 1082G allele in the IL-10
promoter has been validated as a procachectic genotype in an
independent cohort (Deans et al., 2009; Sun et al., 2010). IL-10
has been shown to be elevated in a Myc/mTOR-driven murine
model of cancer cachexia (Robert et al., 2012), as well as in
cachectic patients with colorectal cancer (Shibata et al., 1996).
Likewise, the C allele of the rs6136 polymorphism in the P-selec-
tin gene has recently been associated with weight loss in a largeCell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc. 153
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pendent cohort (Tan et al., 2012). Taken together, these findings
are consistent with a key role for the immune system in the vari-
able presentation of cachexia. However, currently no genome-
wide studies in either animal models or patients have been
performed.
The classical presentation of cachexia is of an extremely thin
and wasted individual. However, heterogeneity in this clinical
presentation is introduced by the current epidemic of obesity.
When healthy individuals develop a chronic disease, the higher
risk associated with obesity is reversed and obesity becomes
‘‘protective,’’ perhaps due to increased adipose and lean tissue
reserves. This is known as the obesity paradox. Mean BMI of
advanced cancer patients is now commonly measured at >25.
There is, however, a subgroup of these overweight patients
who hide gross muscle wasting under a mantle of adipose
tissue. Approximately 40% of overweight or obese patients
with advanced pancreatic cancer have significant skeletal
muscle wasting and this ‘‘myopenic or sarcopenic obesity’’
is an independent risk factor for accelerated demise (Tan
et al., 2009).
As skeletal muscle is a key target in cachexia, it is also relevant
to consider heterogeneity as a result of sexual dimorphism. Men
have greater muscle mass than women and one might assume
that this greater ‘‘reserve’’ would be protective. However, weight
loss and loss of muscle mass are greater in male than female
cancer patients (Baracos et al., 2010), and this may further relate
to a high prevalence of hypogonadism in males (Skipworth et al.,
2011). In fact, male lung cancer patients have shorter survival
than women (Palomares et al., 1996).
Mediators of Cachexia
TNFa
For the past several decades, investigators have searched for
the elusive mediators of cancer cachexia in hope of developing
novel therapeutics to protect against tumor-induced adipose
and skeletal muscle loss. In general, thesemediators are thought
to derive from immune or tumor cells, or the targeted mesen-
chymal tissues undergoing wasting. Considered to be at the
top of this list was the proinflammatory cytokine, TNFa. Chronic
inflammation plays a major role in carcinogenesis, and cancer
cells may rely on production of proinflammatory mediators for
growth, protection from apoptosis, and promotion of angiogen-
esis/metastasis. ‘‘Cachectin’’ was discovered initially in relation
to the wasting associated with leishmaniasis in rabbits (Beutler
and Cerami, 1986) and then was recognized to correspond to
TNFa. This cytokine was subsequently shown in mice to induce
cachexia (Oliff et al., 1987). In vitro, TNFa inhibits both adipocyte
and skeletal myocyte differentiation (Guttridge et al., 2000; Ruan
et al., 2002) and contributes to insulin resistance in part by
impinging on the insulin signaling pathway (Hotamisligil, 1999).
Addition of TNFa is sufficient to promote atrophy in cultured my-
otubes, resulting from the induction of E3 ligase genes that
mediate the breakdown of myofibrillar proteins by the ubiqui-
tin-proteasome pathway (Li et al., 2005; Frost et al., 2007; Moy-
lan et al., 2008; Sishi and Engelbrecht, 2011). Similar results have
been found with the structural homolog of TNFa, TWEAK; this
cytokine is sufficient to induce a cachectic phenotype in part
by the induction of the E3 ligase MuRF1, and the subsequent154 Cell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc.degradation of myosin heavy chain (MyHC) at the thick filament
of the sarcomere (Dogra et al., 2007; Mittal et al., 2010).
Although many rodent tumor models of cancer cachexia
synthesize and secrete TNFa (Llovera et al., 1998), the potential
source of TNFa in humans is unknown. Because TNFa is
frequently synthesized from activated macrophages, and such
cells have been localized to adipocyte stores in cancer patients
with weight loss, it was presumed that immune cells or adipo-
cytes might be sources of the cytokine involved in regulating
energy pathways and lipid mobilization. However, microarrays
from patient biopsies of subcutaneous white adipose tissue
dispute this notion, as changes in inflammatory genes were
undetected (Dahlman et al., 2010), nor were differences
observed in TNFa messenger RNA (mRNA) and protein levels
between noncancer and weight-losing cancer patients (Ryde´n
et al., 2008). The presence of innate immune cells in skeletal
muscle tissue in the tumor-bearing state is rarely described, so
it is unlikely that these cells produce TNFa in the muscle environ-
ment. Systemically, the origin and relevance of TNFa to cancer
cachexia is unclear, as results are conflicted as to whether levels
of this cytokine increase in cancer patients with weight loss (Mal-
toni et al., 1997). Recent trials of anti-TNFa antibodies in patients
with cancer cachexia have shown no benefit (Jatoi et al., 2010).
Thus, in vivo, it is possible that at the concentrations observed,
TNFa is a facilitator, but not sufficient to promote tissue atrophy,
and that synergistic activities from additional tumor or inflamma-
tory factors are needed. Alternatively, it may be that TNFamedi-
ates cachexia for only a subset of cancer types and that effective
therapy would only come from determining those patients who
have elevated TNFa levels. An even less attractive (but more
likely) scenario is that tumors, or host tissues, secrete more
than one cachectic factor, and targeting any one of these will
not be sufficient.
IL-6
One candidate that may cooperate with TNFa, or act alone as
a driver of systemic inflammation in cancer cachexia is IL-6. A
variety of cancer types secrete IL-6 and this can be amplified
by host-derived proinflammatory cytokines (e.g., IL-1). In
contrast to TNFa, circulating levels of IL-6 have been shown to
correlate with weight loss in cancer patients, and importantly,
IL-6 levels correlate with reduced survival (Scott et al., 1996;
Moses et al., 2009). Gain- and loss-of-function experiments in
tumor bearing mice also support the requirement of IL-6 in regu-
lating cachexia (Black et al., 1991; Strassmann et al., 1992;
Strassmann et al., 1993). However, systemic administration of
IL-6, or in vivo electroporation in animal models, suggests that
only supraphysiological doses of IL-6 are capable of inducing
muscle atrophy in the absence of underlying diseases or tumor
(Baltgalvis et al., 2008). The direct regulation of E3 ligase expres-
sion during IL-6-induced muscle atrophy is controversial (Bodell
et al., 2009). In an IL-6-dependent murine model of cachexia,
suppression of muscle protein synthesis occurred early and
increased with progression of weight loss. ATP-dependent
protein degradation increased during the initiation and progres-
sion of cachexia. However, ATP-dependent protein degradation
was not increased until cachexia had progressed beyond the
initial phase. IL-6 receptor antibody blocked cachexia progres-
sion via suppression of muscle protein degradation, while not
rescuing the suppression of synthesis (White et al., 2011).
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lead directly to lipid mobilization or skeletal muscle protein turn-
over, there is general acceptance from both mouse (Bonetto
et al., 2011) and human studies (Wigmore et al., 1997a; Moses
et al., 2009) that IL-6 is produced from activated macrophages
and acts as amediator of cancer cachexia by stimulating the liver
(Castell et al., 1989) to induce an acute phase response (APR;
see Integrative Physiology). The pattern of IL-6 signaling is via
its membrane bound receptor and heterodimer formation by
the signal transducing receptor (gp130). This leads to activation
of the JAK/STAT pathway with translocation of activated STAT
proteins into the nucleus. Targeting IL-6 uniquely may face the
same challenges as anti-TNF therapy. Recent trials of a mono-
clonal anti-IL-6 antibody in weight-losing lung cancer patients
has shown reversal of anorexia, fatigue, and anemia, but no
significant effect on loss of lean body mass (as assessed by
bioelectrical impedance analysis) (Bayliss et al., 2011).
Tumor-Specific Factors
Other mediating factors, such as zinc-a2-glycoprotein (ZAG, or
otherwise known as lipid mobilizing factor) (Taylor et al., 1992)
and proteolysis-inducing factor (PIF) (Todorov et al., 1999),
possess selective activities capable of degrading adipose and
skeletal muscle, respectively. Although each factor has been
linked with weight loss in patients (Mracek et al., 2011; Wigmore
et al., 2000), the existence of a human homolog of PIF and its
role in human cancer cachexia remains under scrutiny (Wieland
et al., 2007).
Myostatin and Activin
A more recent factor, which has captured the attention of many
investigators, is the TGFb family member, myostatin. Animals
(Mosher et al., 2007) and humans (Schuelke et al., 2004), which
are genetic nulls for myostatin, demonstrate dramatic muscle
hypertrophy. A particularly informative case of such instance
occurred in dogs. Whippets—a breed that is normally quite
thin—are used to race in short sprints. Two champion animals
were mated, resulting in a muscle-bound whippet that more
resembled a bulldog (Mosher et al., 2007). This example demon-
strated that the myostatin heterozygotic animals perform well in
this particular setting of muscle exercise, indicating that at least
a partial loss of myostatin results in better performance; it is
less clear whether the complete loss of myostatin improves
muscle function, and there are some indications that it
does not, although the caveat of such results is derived frommy-
ostatin deletion occurring throughout development (Matsakas
et al., 2012).
Myostatin is synthesized and secreted mainly from skeletal
muscle cells and signals through the activin type II receptor,
which then recruits an Alk family kinase, resulting in the activa-
tion of a Smad2 and Smad3 transcription factor complex (Tren-
delenburg et al., 2009; Sartori et al., 2009). Overexpression of
myostatin in mice leads to pronounced skeletal muscle atrophy
(Zimmers et al., 2002), and conversely, inhibition by various
genetic means promotes a doubling in muscle mass and myo-
fiber size (Bogdanovich et al., 2002; Whittemore et al., 2003;
Lee et al., 2005; Welle et al., 2007). Although the mechanism
by which myostatin promotes muscle loss has not been eluci-
dated fully, findings suggest that theremay bemultiple pathways
that impinge both by inhibiting Akt and thus the downstream
TORC1 pathways that promote protein synthesis (Trendelen-burg et al., 2009; Lokireddy et al., 2011) and by activation of
SMAD2/3 that mediates inhibition of genes associated with
muscle differentiation (Trendelenburg et al., 2009; Sartori et al.,
2009). However, these mechanisms have yet to be tested in
the tumor-bearing state, although in animal models and
patient muscle biopsy samples, evidence does indicate that my-
ostatin levels and myostatin-associated signaling are activated
as a result of a tumor burden (Acharyya et al., 2005; Aversa
et al., 2012).
In addition to myostatin, there are other TGF-b family
members induced by inflammatory cytokines. In particular, Acti-
vin A has been found to be upregulated in skeletal muscle after
activation of the TNFa/TAK-1 signaling pathway (Trendelenburg
et al., 2012). Furthermore, blockade of Activin A in this model is
sufficient to block atrophy. This finding demonstrates that,
similar to the case of individual cytokines, blocking individual
TGF-b family members such asmyostatin alonemay not be suffi-
cient in settings of cancer cachexia.
Rather than using an antibody against myostatin itself, another
approach has been to target a common receptor of bothmyosta-
tin and the Activins—the Activin type II receptor B. Both Activin A
and Activin B are potent growth and differentiation factors with
a broad spectrum of biological effects, including modulation of
embryogenesis, neuroprotection, apoptosis, and fibrosis.
Synthesis and release of activins are stimulated by inflammatory
cytokines, Toll-like receptor ligands, and oxidative stress
(Hedger et al., 2011). Many human cancers present altered
expression of Activin A associated with amoremalignant pheno-
type. Indeed, as noted, tumors can also induce muscle itself to
induce Activin A (Trendelenburg et al., 2012). Elevated circu-
lating Activin A levels have been noted in patients with cancer
and have been associatedwith the presence of bonemetastases
(Leto et al., 2006). The biological activity of activins is closely
regulated by several factors that antagonize or modulate them,
including inhibin, follistatin, Cripto, BAMBI, and the Activin-bc
dimer (Gold and Risbridger, 2012).
In recent studies, an ActRIIb receptor-based trap was used to
treat cancer cachexia in four distinct mouse models of cancer
cachexia (Zhou et al., 2010; Benny Klimek et al., 2010). Treat-
ment with the ActRIIb trap blocked cachexia in the C26 model
of cancer cachexia without effecting tumor growth (Zhou et al.,
2010). Nevertheless, these mice experienced a 30% increase
in survival rates, suggesting that this approach might be helpful
in human cancer cachexia. Myostatin blocks skeletal muscle via
the ActRIIb/Smad2,3 pathway. Interestingly, treatment of IGF1
can dominantly revert myostatin inhibition of Akt, suggesting
that IGF1 as a drug would be helpful even in settings where my-
ostatin or Activin are active (Trendelenburg et al., 2009).
However, in the context of cancer, the use of a growth factor
like IGF1 is clearly problematic, since IGF1 can be associated
with cancer progression. The fact that skeletal muscle mass is
preserved by blocking the myostatin/activin pathway does not
mean that over activity of this pathway is responsible for
cachexia in all murine models or humans. This lack of causality
may not be an issue if blockade of this pathway is sufficient to
induce clinically meaningful inhibition of cachexia.
Neuroendocrine Change
Cachexia does not exist in isolation. Advanced cancer is associ-
ated with an array of symptoms, including pain, which can leadCell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc. 155
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Figure 1. Integrative Physiology of Cancer
Cachexia
The tumor is associated with activation of proin-
flammatory and neuroendocrine responses.
These result in reduced food intake and metabolic
change. Adrenergic activation and tumor-related
lipolytic factors lead to enhanced lipolysis. The
effects of hypogonadism, insulin resistance,
adrenergic activation, and systemic inflammation
coupled with semistarvation lead to muscle
atrophy. Liver export protein synthesis is stimu-
lated as part of the acute phase response. In
addition, futile substrate cycles (such as the Cori
cycle) contribute to hypermetabolism.
Cell Metabolism
Reviewto activation of the neuroendocrine stress response. Glucocorti-
coids are a key component of the stress response and are well
recognized to facilitate muscle wasting in conditions associated
with severe systemic inflammation, such asmajor sepsis. Recent
evidence suggests that such an effect may be mediated by
downregulated expression of the nuclear cofactor PGC-1b,
leading to increase expression of the E3 ligases MAFbx and
MuRF1 (Menconi et al., 2010). In patients with cancer cachexia
some studies have suggested a trend toward elevated urinary
cortisol excretion (Drott et al., 1988), whereas other studies
have suggested that while the pituitary-adrenal axis remains
intact, it is not over active (Chauhan et al., 2012; Dev et al.,
2011). Advanced cancerpatientsdo, however, commonly receive
large pharmacological doses of predisolone or dexamethasone
that are recognized to induce a proximal myopathy, and this
can contribute to overall muscle wasting. However, in a murine
model of cancer cachexia in which both circulating glucocorti-
coids and IL-6 were elevated, inhibition of glucocorticoid activity
with the receptor antagonist RU-486 did not influence the evolu-
tion of cachexia (Rivadeneira et al., 1999), suggesting a more
complex scenario. For example, given the primary role of gluco-
corticoids in blocking inflammation, the moderate use of gluco-
corticoids in the setting of cancer cachexia (where inflammation
is often elevated) may bring these pathways down to physiologic
levels, resulting innet improvement.Howeverwhen largedosesof
dexamethasone are used, dramatic myopathy may be observed.
The effects of advanced cancer on the hypothalamus are
selective with preservation/activation of the adrenal axis, but
suppression of gonadal function (Grossberg et al., 2010), which
may in part be opioid-related (Skipworth et al., 2011; Dev et al.,
2011). Muscle loss secondary to reduced testosterone may be
via regulation of myostatin, c-Jun NH2-terminal kinase, Notch,
and Akt signaling pathways (Kovacheva et al., 2010). Testos-
terone loss decreases voluntary activity in a mouse model and156 Cell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc.dramatically reduces levels of the tran-
scriptional coactivator PGC-1a, associ-
ated with decreased mitochondrial
biogenesis (Ibebunjo et al., 2011). There
are several trials of selective androgen
receptormodulators (SARMs) in progress
in human cancer cachexia.
Reduced insulin sensitivity is
commonly present in both human and
animal models of cancer cachexia
(Agustsson et al., 2011; Asp et al., 2010:Yoshikawa et al., 2001) and may contribute to muscle wasting
via reduced anabolic signaling in response to a meal (Cuthbert-
son et al., 2005). This state of insensitivity may relate to reduced
GLUT4 protein expression in both basal and insulin-stimulated
states, due to selective inhibition of insulin-stimulated phosphor-
ylation of IRS1 (Yoshikawa et al., 1999). Possible mediators
include proinflammatory cytokines (McCall et al., 1992), central
melanocortin signaling (Parton et al., 2007), leptin (Smiechowska
et al., 2010), and elevated levels of free fatty acids frommobilized
lipid reserves (Zechner et al., 2012). Although combined treat-
ment with growth hormone, insulin, and indomethacin has
been shown to alleviate cancer cachexia in a mouse model
(Chen and Qiu, 2011), treatment of patients with exogenous
low-dose insulin did not add to the benefits of nutrition and
nonsteroidal anti-inflammatory drugs in relation to lean tissue
mass (Lundholm et al., 2007).
Integrative Physiology
The human body responds to stress with dramatic resilience and
ultimately aims to maintain homeostasis. Some of the major
tumor-related stressors that contribute to cachexia along with
a variety of the natural responses are shown in Figure 1. These
responses are often a double-edged sword. For example,
although the hepatic acute phase protein response is useful in
acute injury (e.g., hemostasis and fighting microbial invasion), if
the response is prolonged and potentially futile (as in advanced
cancer), then what results is an accelerated loss of skeletal
muscle and excess morbidity and mortality. Knowledge about
the integrative physiology of the cancer host and assessment
of the relative benefits or deficits of each response is vital to plan-
ning appropriate intervention.
Decreased Food Intake
Anorexia is a common symptom in advanced cancer and is often
compounded by secondary problems such as pain, depression,
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multifaceted and incompletely understood and has been the
subject of reviews elsewhere (Laviano et al., 2008). In essence,
mainly proinflammatory signaling from peripheral tissues
(including the tumor) may increase activity of pro-opiomelano-
cortin neurons in the hypothalamus resulting in anorexia and
reduced food intake (Grossberg et al., 2010).
The role of anorexia and reduced food intake varies from one
animal model of cachexia to another. In some there is little
evidence of reduced food intake, whereas in others it is a major
issue and increases with progression of tumor growth/cachexia
(Bennani-Baiti and Walsh, 2011). Food intake can vary by as
much as 50% in free-living, healthy, weight-stable individuals
and accurate measurement of food intake in clinical studies is
problematic. Thus, it is difficult to be definitive about the role of
food intake in cancer cachexia. Patientswith advancedGI cancer
generally have a low mean dietary intake (1,700 Kcal/day or
1.26 times basal metabolic rate) (Bosaeus et al., 2001). This is
comparable with energy requirements in bedridden or chair-
bound people, but insufficient under conditions with even low
physical activity. In lung cancer patients, (Staal-van den Brekel
et al., 1994), food intake is also generally low, but with a clear
differential between weight-losing and weight-stable patients.
Cancer patients with evidence of systemic inflammation have
a reduced food intake (Wigmore et al., 1997b) suggesting
a possible role for proinflammatory cytokines in the suppression
of appetite.
Hypermetabolism
Total energy expenditure (TEE) is divided into resting energy
expenditure (REE), diet-induced energy expenditure (DEE), and
the energy cost of physical activity (AEE). Approximately 50%
of patients are hypermetabolic (REE > 110% of predicted), and
weight-stable patients tend to have a lower REE, but must still
have a very low level of physical activity to maintain energy
balance (Bosaeus et al., 2001). Energy expenditure varies
between different animal models with some being hypermeta-
bolic (Bennani-Baiti and Walsh, 2011). In at least one model,
the metabolic rate is increased at the start of cachexia but
decreases with progressive tumor growth (Zylicz et al., 1990).
The peripheral mechanisms underlying hypermetabolism in
cancer cachexia are varied and complex. Hypermetabolism
has been related to the presence of an elevated adrenergic state
(Hyltander et al., 1991) or systemic inflammation (Falconer et al.,
1994). These associations may be mediated centrally via path-
ways that include melanocortin type 4 receptors (Grossberg
et al., 2010). Futile substrate cycles are thought to contribute.
Human tumors are known to have high glucose uptake (the basis
of deoxyglucose positron emission transition: PET scanning) and
a high rate of glycolysis/lactate production. Such high rates of
glycolysis persist even in the presence of oxygen (Warburg
effect). Increased glucose uptake/glycolysis has been ascribed
to abnormal mitochondrial function (John, 2001), overexpression
of type II hexokinase due to gene demethylation (Goel et al.,
2003), overexpression of various oncogenes (e.g., c-Myc, Ras,
Akt, Pik3ca), or loss of tumor suppressors (p53 and Vhl) that
increase dependence on glucose (Hu et al., 2011; Dang, 2009)
or simply the hypoxic environment of the tumor and hypoxia-
inducible factor I effects on glucose metabolism. Excess lactate
from the tumor can be converted back to glucose in the liver(Cori cycle) by pathways that lead to the net consumption of
ATP. Increased Cori cycle activity has been documented in
weight-losing cancer patients (Holroyde et al., 1975), however,
like REE, there appears to be both marked heterogeneity
and a poor correlation between excess lactate production and
tumor burden (Holroyde et al., 1979). Overall glucose flux (gluco-
neogenesis and glycogenolysis) has been shown to be
increased in weight-losing cancer patients (Ede´n et al., 1984),
and such flux has been estimated to contribute up to 40% of
the increase in energy expenditure in metastatic cancer (Lund-
holm et al., 1982). Gluconeogenesis from glycerol or alanine is
not thought to contribute significantly to the energy drain (Ede´n
et al., 1984).
An alternative mechanism that may contribute to hypermetab-
olism is increased expression of mitochondrial uncoupling
proteins (UCPs). Adaptive thermogenesis is a unique process
whereby increased expression of UCP 1 in the mitochondria of
brown-adipose tissue (BAT) leads to dissipation of the proton
gradient so that oxygen consumption is no longer coupled to
ATP synthesis and heat is generated. Adult humans have meas-
ureable amounts of brown fat (Virtanen et al., 2009; van Marken
Lichtenbelt et al., 2009). Muscle UCP-3 (but not UCP-2) mRNA
levels have been shown to be elevated in weight-losing patients
with upper GI cancer compared both with healthy controls and
cancer patients who had not lost weight (Collins et al., 2002).
However, UCP-2 and UCP-3 mRNA and UCP-3 protein were
not elevated (DeJong et al., 2005) in weight-losing patients
with pancreatic cancer. Changes in UCPmRNA levels are unreli-
able predictors of uncoupling protein activity and further studies
are warranted. A recent study in knockout mice raised the possi-
bility that activin signaling plays a role in governing energy
balance via mitochondrial uncoupling (Li et al., 2009). As indi-
cated above, increased activin/myostatin signaling has been
implicated in several murine models of cancer cachexia (Zhou
et al., 2010; Benny Klimek et al., 2010).
It is also possible to ascribe a component of ‘‘hypermetabo-
lism’’ to altered body composition. While skeletal muscle mass
is markedly reduced in cancer cachexia (Fearon and Preston,
1990; Cohn et al., 1981), there is relative preservation of visceral
protein mass (with little loss of heart or kidney volume, and no
loss of liver and spleen volume) (Heymsfield and McManus,
1985). If liver mass increased by only 500 g, it would add an
incremental REE of 100 Kcal/day. A recent study used sequential
CT scans in patients with colorectal cancer to document
progressive increases in liver and spleen mass and found a posi-
tive linear relationship with REE (Lieffers et al., 2009). It was esti-
mated that 2 kg of fat mass would be lost in the last 3 months of
life due to these changes alone. The increase in liver mass with
cancer progression may be due to the presence of intrahepatic
metastatic disease coupled with the activation of the
hepatic APR.
Systemic Inflammation and the Hepatic APR
Hypoalbuminaemia has long been considered a key clinical
feature of cancer cachexia. In cancer patients with systemic
inflammation and an APR, the synthesis of positive reactants
increases (Preston et al., 1998), whereas albumin synthesis rates
are unaltered (Fearon et al., 1998). Hypoalbuminaemia must
therefore be due to increased transcapillary escape and
increased degradation. Thus, increased hepatic synthesis ofCell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc. 157
Figure 2. Fat Atrophy Is Regulated by
Tumor Induced Lipolysis
Lipid-mobilizing factors trigger fat wasting by
acting via b-adrenoreceptors (b-AR) and G
protein-coupled receptors (Ga) to form cAMP or
cGMP that in turn stimulate protein kinase A (PKA)
activity. PKA subsequently phosphorylates
hormone-sensitive lipase (HSL) that hydrolyzes
triglycerides (TG) into to release of free fatty acids
(FFA) and glycerol into the circulation. In addition
to HSL, adipose triglyceride lipase (ATGL) is also
involved in adipose TG hydrolysis.
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negative APRs. In the context of the metabolic response to
injury/inflammation (where dietary intake of protein may be negli-
gible), the body prioritizes maintenance of hepatic export protein
synthesis by concomitant net mobilization of protein from
peripheral tissues such as skeletal muscle. There is a mismatch
in amino acid composition between skeletal muscle and acute
phase proteins and it has been suggested that during a low
food intake this may amplify the need for muscle mobilization
(Reeds et al., 1994). In this way, an APR may accelerate muscle
wasting in cachectic cancer patients. As stated previously, IL-6
is thought to be the main regulator of the APR in human hepato-
cytes (Castell et al., 1989). A recent study (Bayliss et al., 2011)
showed that anti-IL-6 antibody in lung cancer patients had no
significant effect on lean body mass. However the sample size
was not selected to address this issue and there were no specific
measurements of skeletal muscle mass.
Fat Atrophy
Key Role of Increased Lipolysis
Fat is lost more rapidly than lean tissue in cancer cachexia (Fou-
ladiun et al., 2005). This loss of adipose tissue results partly from
reduced food intake, as well as from tumor factors and systemic
inflammatory cytokines that function by either inhibiting lipogen-
esis or by promoting lipolysis. In vitro, inflammatory cytokines
such as TNFa are potent inhibitors of lipogenesis by suppressing
the synthesis of essential adipocyte differentiation transcription
factors. Although exogenous TNFa can achieve similar results
in animal models at supraphysiological levels (Oliff et al., 1987),
such effects have not been reproduced in weight-losing cancer
patients, suggestive of an alternative mechanism. Results from
clinical studies suggest that adipose depletion in cachexia
occurs by lipolysis (Zuijdgeest-van Leeuwen et al., 2000; Ryde´n
and Arner, 2007). In thismodel, fat atrophy results from themobi-
lization of lipids that constitute 95% of fat cell volume. Specifi-
cally, triglycerides are hydrolyzed to free fatty acids (FFAs) and
glycerol, which are then released in the circulation. The rate-
limiting enzymes catalyzing this reaction are the hormone
sensitive lipase (HSL) and adipose triglyceride lipase (ATGL)
(Zimmermann et al., 2004). Both HSL activity and plasma FFA
and glycerol increase considerably in cancer cachexia patients
(Ryde´n and Arner, 2007). HSL activation occurs through
a signaling pathway initiated by prolipolysis factors that act on
b-adrenoceptors (b-AR) coupled to G proteins (Gas). This activa-
tion triggers adenylate cyclase and production of cyclic AMP
(cAMP) that binds and further activates protein kinase A (PKA),
which in turn phosphorylates and produces similar activation158 Cell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc.of HSL. In primates, cAMP levels are regulated through the
balance of b-ARs and a2-AR receptors, coupled to Gai proteins
that instead inhibit adenylate cyclase activity. Human adipose
cells contain additional receptors stimulated by brain and atrial
natriuretic peptides that activate guanylate cyclase to generate
cGMP. This second messenger acts in concert with cAMP to
stimulate PKA and in turn HSL activity and FFA plus glycerol
(Figure 2). Under noncatabolic conditions, insulin itself acts
through a signaling cascade that leads to the activation of phos-
phatidyl inositol kinase (PI3K) that depletes cAMP levels, thus
stimulating phosphodiesterase and subsequent hydrolysis to 50
AMP. However, since cancer cachexia is commonly associated
with insulin resistance, this antilipolytic arm is removed, thereby
furthering the adipose atrophy response.
Although studies of cultured cells and animal models support
the role of cytokines and lipid-mobilizing factor (ZAG) in
promoting fat breakdown (Inadera et al., 2002; Beck and Tisdale,
2004; Bing et al., 2004), in GI cancer patients (with unintentional
weight loss, low serum albumin, and impaired nutritional status)
lipolysis was not necessarily related to adipocyte-generated
cytokines, nor an increase in immune cell infiltrates (Ryde´n
et al., 2008), although in an independent study ZAG levels did
rise (Mracek et al., 2011). There was also no evidence of cell
death or necrosis, supporting the notion that loss of fat mass is
due to atrophy rather than a reduction in adipocyte cell number.
Fat-Muscle Crosstalk
Lipid-induced insulin resistance has long been studied in rela-
tion to obesity and type II diabetes. One hypothesis is that intra-
cellular accumulation of diacylglycerol triggers activation of
novel protein kinases C with subsequent impairments in insulin
signaling (Samuel et al., 2010). A recent study in mice bearing
the IL-6 producing, procachectic C26 tumor showed that
genetic ablation of adipose triglyceride lipase prevented the
increase in lipolysis and the net mobilisation of adipose tissue
associated with tumor growth (Das et al., 2011). Unexpectedly,
skeletal muscle mass was preserved and activation of proteaso-
mal degradation and apoptotic pathways in muscle was
averted. Ablation of hormone-sensitive lipase had similar, but
weaker, effects. This study opens up the possibility that hitherto
unrecognized, physiologically important crosstalk between
adipose tissue and skeletal muscle exists in the context of
cancer cachexia (Zechner et al., 2012). The mediators of such
crosstalk could include myokines, adipokines, or free fatty
acids. It is also important to recognize that the genetically modi-
fied mice used in these studies are not normal and that
secondary effects of the genetic manipulation may be important.
A recent study has shown progressive accumulation of
Figure 3. Atrophy and Hypertrophy
Pathways in Skeletal Muscle
Skeletal muscle mass is controlled by the balance
between atrophy and hypertrophy pathways. The
main hypertrophy signaling is via the IGF receptor
and Akt/mTOR. Atrophy pathways include the
myostatin/Activin ligands, which act via the ACTRII
receptor and Smad 2,3—these ligands inhibit Akt
mediated protein synthesis, and block the upre-
gulation of muscle differentiation genes, including
MyoD and myogenin. Also mediating atrophy are
the inflammatory cytokines, such as IL-1 and TNF;
in skeletal muscle, these cytokines induce the
secretion of ActivinA from muscle, causing cross-
talk to SMAD2/3 signaling.
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degrees of cachexia (Stephens et al., 2011), again emphasizing
the potential importance of lipids as markers/mediators in
muscle atrophy.
Muscle Atrophy
Central Role of E3 Ligases in Atrophy
Loss of skeletal muscle mass is generally due to reduced protein
synthesis, increased degradation, or a relative imbalance of the
two (Glass, 2010). The signaling pathways that are thought to
control these processes are shown in Figure 3. One prominent
subset of the procachecticmolecularmechanisms can be traced
as follows: proinflammatory cytokines such as TNFa, TWEAK, or
IL-1 signal into two established pathways, the NF-kB pathway
(weakly in the case of TWEAK) and p38 MAP kinase. These
two signaling mediators are required to upregulate the expres-
sion of the key E3 ligases (muscle RING finger-containing
protein 1, MURF1, and muscle atrophy F box protein, MAFbx,
otherwise known as Atrogin-1), which mediate sarcomeric
breakdown and inhibition of protein synthesis (Glass, 2010).
MuRF1 is upregulated in multiple settings of muscle atrophy
(Bodine et al., 2001a). This E3 ubiquitin ligase is responsible for
mediating the ubiquitination of the thick filament of the sarco-
mere—MyHC (Clarke et al., 2007), and other thick filament
components (Cohen et al., 2009). The cytokine TWEAK, in partic-
ular, induces MuRF1 upregulation via NF-kB, resulting in MyHC
loss (Mittal et al., 2010). Inhibition of classical NF-kB is sufficient
to significantly decrease tumor-induced muscle loss, at least in
mice, in part, by inhibiting the upregulation of MuRF1 (Cai
et al., 2004; Moore-Carrasco et al., 2007).
The RING finger in MuRF1 binds zinc, which is required for its
activity, as is the case with all RING finger-containing E3s (Bor-
den and Freemont, 1996). One recent study demonstrates that
zinc accumulates during cachexia, speculating that this may
help induce ubiquitination by zinc-dependent E3s (Russell
et al., 2010). MAFbx/Atrogin-1 also serves as a high-fidelity
marker of acute muscle atrophy, being upregulated in multiple
settings of cachexia (Gomes et al., 2001), in addition to immobi-Cell Metabolism 1lization, denervation, and glucocorticoid
excess (Bodine et al., 2001a). MAFbx up-
regulation occurs via p38 activation (Li
et al., 2005) and by the induction of the
C/EBPb transcription factor, which itself
is activated through p38 phosphorylation(Zhang et al., 2011). MAFbx induces the ubiquitination of an
eIF3f, which is part of the protein translation machinery (Csibi
et al., 2009; Lagirand-Cantaloube et al., 2008). However, it is
not clear if this is sufficient to decrease protein synthesis.
Some studies in cachectic tumor-bearing rats indicate that if
amino acids are provided there is an increase in protein
synthesis, but the breakdown of proteins outpaces this increase
(Temparis et al., 1994). If the tumor-bearing rats were nutrition-
ally deprived of amino acids, a concomitant decrease in protein
synthesis and an increase in protein turnover would be observed
(Temparis et al., 1994). The demonstration that both MuRF1 and
MAFbx contribute to skeletal muscle atrophy was provided by
studies of knockout animals—in the absence of either MuRF1
or MAFbx, rates of atrophy are diminished (Bodine et al.,
2001a). Thus, inflammatory cytokines secreted by tumors
directly induce signaling pathways that upregulate enzymes
that induce skeletal muscle protein turnover.
The E3 ligase Fbxo40 may be able to contribute to atrophy by
inducing the ubiquitination of IRS1 and thereby short-circuiting
the IGF1/IGF1R/IRS1 pathways and downstream protein
synthesis activation (Shi et al., 2011). Fbxo40 is able to cause
IRS1 to be degraded upon its phosphorylation by the IGF1R
(Shi et al., 2011). Under settings where protein synthesis is
ongoing, this would not be expected to decrease signaling in
a sustained fashion, because the degraded IRS1 could simply
be re-synthesized, and signaling could thereby continue.
However, under conditions where protein synthesis is blocked,
IRS1 would not be replenished, and IGF1 signaling would
thereby be silenced. Some indication that this might happen is
supported by a recent study suggesting that Fbxo40 is upregu-
lated upon denervation. It remains to be determined whether this
happens in other settings of muscle atrophy (Ye et al., 2007).
Hypertrophy Signaling and Links with Atrophy Pathways
Opposing skeletal muscle atrophy are those pathways that
induce muscle hypertrophy. One of the best-characterized
mechanisms for inducing hypertrophy is through IGF1 (insulin-
like growth factor 1) signaling. IGF1 is upregulated in skeletal
muscle normally during resistance exercise (Singh et al., 1999),6, August 8, 2012 ª2012 Elsevier Inc. 159
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ular muscles depending on work and resistance. The pathway
that mediates hypertrophy downstream of IGF1 activation is
IRS1/PI3K/Akt (Rommel et al., 2001). Transgenic mice in which
Akt is transgenically expressed and inducibly activated in skel-
etal muscle demonstrate dramatic hypertrophy upon the activa-
tion signal (Izumiya et al., 2008; Lai et al., 2004; Pallafacchina
et al., 2002), helping to prove that this is the pathway that is suffi-
cient to mediate hypertrophy downstream of IGF1 upregulation.
Akt induces activation of protein synthesis by blocking repres-
sion of mTOR, which in turn maintains muscle mass through
two distinct complexes, known as TORC1 and TORC2 (Bent-
zinger et al., 2008; McGee et al., 2008). The TORC1 complex
requires an adaptor protein known as Raptor, which is required
for normal muscle maintenance (Bentzinger et al., 2008).
TORC1 signals to the p70S6 kinase and 4E-BP pathways, which
induce ribosome formation and induce protein synthesis.
TORC2 signaling controls autophagy, which also plays a role in
muscle maintenance (Mammucari et al., 2007; Mieulet et al.,
2007; Zhao et al., 2007). Blockade of Akt signaling to TORC1,
for example by use of rapamycin, inhibits compensatory hyper-
trophy (Bodine et al., 2001b; Izumiya et al., 2008), as does
blockade of Akt induced phosphorylation of GSK3 (Badorff
et al., 2002; Morisco et al., 2001; Rommel et al., 2001; Wang
et al., 1999). Under atrophy conditions, autophagy is induced
in addition to ubiquitin-mediated proteolysis. However while
blockade of ubiquitin signaling, for example using the protea-
some inhibitor Velcade, has been demonstrated to result in
healthy preserved muscle (Krawiec et al., 2005), developmental
blockade of autophagy results in pathologicmuscle (Mammucari
et al., 2007). In addition to activating TORC1 signaling, Akt also
phosphorylates the Foxo (or Forkhead) family of transcription
factors. Foxo1 and Foxo3 play a key role in inducing transcrip-
tional upregulation of MuRF1 and MAFbx (Sandri et al., 2004;
Stitt et al., 2004). Apparently these transcription factors are
required, since IGF1/Akt mediated Foxo phosphorylation and
subsequent inhibition of Foxo transport to the nucleus is suffi-
cient to block the upregulation of the E3 ligases. In addition,
transgenic overexpression of Foxo3 in skeletal muscle is suffi-
cient to induce dramatic skeletal muscle wasting (Kamei et al.,
2004), while recent evidence supports that inhibition of Foxo
spares muscle loss in a mouse model of cancer cachexia
(Reed et al., 2012).
Links with Protein Synthesis and Degradation
The mass of protein within a muscle is regulated by the net inter-
play between protein synthesis and degradation. In rodent
models of cancer-associated muscle wasting, both decreased
synthesis and increased degradation have been described
(Samuels et al., 2001; Smith and Tisdale, 1993). There have
only been a few direct measurements of protein synthesis in hu-
mans with cancer cachexia. Protein synthesis has been shown
to be decreased (Emery et al., 1984) with only indirect evidence
available on the issue of protein degradation.
Transcriptional activation of ubiquitin proteasome pathway
(UPP) components has been found in the skeletal muscle of
both rodent models (Lecker et al., 2004) and patients with
pancreatic, upper gastrointestinal (UGI), or liver cancer (Williams
et al., 1999; Bossola et al., 2003; Khal et al., 2005), and this was
associated with increased protein or proteolytic activity in vitro160 Cell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc.(Bossola et al., 2003; Khal et al., 2005). It has also been reported
that skeletal muscle calpain, MAFbx, and MuRF1 mRNA re-
mained unchanged in the skeletal muscle of gastric cancer
patients, while calpain activity was elevated even in the absence
of weight loss (Smith et al., 2011). In lung cancer patients, while
UPP genes in skeletal muscle are not increased, elevation of
cathepsin B mRNA has been observed (Jagoe et al., 2002).
Using genome-wide transcript analysis of sequential quadri-
ceps muscle biopsies in patients before and after curative
surgery for upper gastrointestinal cancer, a recent study has
shown that 1,868 genes were regulated in the cachectic state.
Ontology analysis demonstrated that these gene products be-
longed to both anabolic and catabolic biological processes,
which were overwhelmingly downregulated in the cachectic
state. No literature-derived genes from preclinical cancer
cachexia models (e.g., atrogenes) were found to be elevated in
cachectic muscle (Gallagher et al., 2012). These findings are
consistent with the notion of a predominant decrease in
synthesis in the early phase of cancer cachexia. Interestingly, it
has been suggested that MAFbx expression is a poor index of
muscle proteolysis and may instead be predominantly linked
with controlling protein synthesis (Attaix and Baracos, 2010).
In addition to regulating UPP, Foxo transcription factors
directly regulate genes coding for the autophagy pathway, which
like the ubiquitin system also contributes to the degradation of
muscle proteins to promote atrophy (Mammucari et al., 2007;
Zhao et al., 2007). In autophagy, organelles are sequestered in
autophagosome vacuoles that fuse with lysosomes and become
digested by lysosomal enzymes (Lum et al., 2005). Autophagy
genes and the lysosomal proteolytic system are activated during
denervation and cancer, and in both cases contribute to atrophy
through the activity of Foxo (Mammucari et al., 2007; Zhao et al.,
2007; Reed et al., 2012). A unique finding determined that anal-
ogous to Akt, Foxo3 is negatively regulated by PGC-1a (Sandri
et al., 2006). PGC-1a is itself downregulated in muscles from
tumor-bearing mice and other wasting conditions, and trans-
genic expression of PGC-1a rescues muscle loss in part by
inhibiting Foxo3 and through the production of metabolic prod-
ucts. PGC-1a is highly induced during exercise, and one of the
primary roles of this factor is to regulate mitochondrial biogen-
esis and oxidative phosphorylation in myofibers, characteristic
of type I, fatigue-resistant, muscles (Lin et al., 2002; Baar et al.,
2002). Interestingly, in cancer cachexia, muscle atrophy is selec-
tive to type II fast twitch myofibers, while type I oxidative fibers
are relatively spared of similar catabolic effects (Mendell and En-
gel, 1971). Therefore, it is possible that this sparing effect results
from PGC-1a inhibition of Foxo3 activity in type I myofibers.
Attempts to screen for PGC-1a activators (Arany et al., 2008)
represents a promising therapeutic avenue to prevent muscle
atrophy in cancer or other catabolic conditions.
Links between Atrophy and Dystrophy
Despite the clear discrepancies between muscular dystrophy
and cancer cachexia phenotypes, it is of interest to note that in
settings of cancer cachexia theremay be a loss of the dystrophin
protein (Acharyya et al., 2005), and dystrophin-associated
complex member, nNOS (Suzuki et al., 2007). This structural
loss causes a decrease in membrane integrity and potentially
compromises muscle membrane from the nourishing extracel-
lular matrix. This results in increases in MuRF1/MAFbx activity,
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2005). This finding links dystrophy mechanisms with those
seen in atrophy; however, it is important to note that in the
case of cachexia, there is no inherent genetic issue disrupting
the dystrophin protein and its associated complex members.
This may explain why a restoration of active protein synthesis,
for example by exogenous treatment with myostatin inhibitors,
apparently provides sufficient compensatory trophic support to
return skeletal muscle to competence (Zhou et al., 2010). An
additional approach might be the use of PGC-1a activators,
which in dystrophin deficient mice was seen to mitigate muscle
turnover (Handschin et al., 2007).
Treatment of Cancer Cachexia
It is widely recognized that cachexia is best managed within
a multimodal approach, including basics such as nutrition and
exercise (Fearon, 2008; Lundholm et al., 2007; Del Fabbro
et al., 2011). For example, it is difficult to imagine successful
management of a cancer patient with sarcopenic obesity that
does not involve an exercise program: increased physical
activity has the potential to reduce adiposity, increase muscu-
larity, lower chronic inflammation, increase muscle mitochon-
drial content and function through PGC-1a expression, and
improve insulin sensitivity. Moreover, a powerful stimulus to
increase food intake (e.g., potentially with ghrelin agonists or
melanocortin-4 receptor antagonists) would likely improve the
mass/function ofmany tissues and organs in patients particularly
where wasting was predominantly due to reduced food intake.
Independent of such general management, recent advances in
molecular and cell biology have provided a range of novel drug
targets relevant to the specific treatment of cachexia. Interven-
tions could be either upstream (e.g., antagonize key mediators
of systemic inflammation) or downstream (e.g., block catabolic
pathways or stimulate anabolic pathways in skeletal muscle).
Accepting the issues of heterogeneity and redundancy,
upstream targets have the advantage of affecting multiple
aspects of cachexia. For example, although IL-6 is known to
be the main mediator of the hepatic acute phase response in hu-
mans, this cytokinemay also play a role in anorexia, pain, fatigue,
anemia, edema, and muscle loss. By contrast, myostatin acts as
a physiological brake to continued growth of skeletal muscle and
is therefore a potential downstream target. Blockade of myosta-
tin offers a specific method to induce muscle hypertrophy inde-
pendent of the provision of anabolic signals (e.g., growth
hormone, IGF-1), which at least theoretically might stimulate
cancer growth. One key question for a downstream approach
(that does not tackle reduced food intake) is how to supply
enough substrate to support muscle maintenance/hypertrophy.
It is also important to know whether a patient will make use of
a restored skeletal muscle mass in the face of ongoing systemic
inflammation and related fatigue.
Therapies based on a variety of new targets are currently in
phase I and phase II clinical trials in cancer patients, and the
demonstration of their potential efficacy to stem losses of weight
and muscle, alter physical function, and impact quality of life will
be available in the foreseeable future. Two programs that have
advanced to phase III studies include a SARM and a ghrelin
analog. It is likely that combinations that address low food intake,
low levels of exercise, systemic inflammation, and muscleatrophy will form the ultimate successful therapeutic paradigm.
The promise that identification of critical cachexia transcription
and cotranscriptional factors (e.g., FOXO, STAT, NF-kB) as
hub genes is a tantalizing prospect for yet further therapeutic
developments.
In Conclusion
The mechanisms of cancer cachexia are complex and multifac-
torial. Preclinical models provide a robust setting for exploration
of potential mediators, signaling pathways, and therapeutic
targets. Equally, there is no ideal rodent model for the human
situation. Nevertheless, common themes emerge in terms of
cytokine/neuroendocrine-driven changes in food intake, energy
expenditure, adipocyte lipolysis, and altered hepatic and skel-
etal muscle protein synthesis/degradation.
Cancer cachexia, like other settings of cachexia, used to be
regarded as an unfortunate consequence of the underlying
disease, but not something to treat beyond making an attempt
to normalize nutritional intake. With the increased understanding
of conserved molecular mechanisms inducing lean muscle
atrophy or hypertrophy, combined with findings at least in
tumor-bearing animal models that blocking cachexia on its
own can decrease mortality and morbidity, it is becoming more
acceptable to view cachexia as a distinct entity and to treat it
as a discrete condition. It remains to be seen which treatments
will turn out to be successful, but prior experience in humans
and certain animal models provide inductive evidence that
a successful treatment will combine nutritional support and exer-
cise with pharmacological agents that block the breakdown of
skeletal muscle (e.g., myostatin receptor blockers, cytokine
pathway inhibitors) or induce muscle hypertrophy. Once cancer
cachexia can be inhibited, it will then be of interest to determine
whether patients can endure more prolonged cancer therapy,
thereby providing an additional benefit. Further, it will be impor-
tant to learn whether the simple inhibition of cachexia—and thus
restoration of the internal milieu of the host—may have an
adjoining effect on the growth of the tumor.
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